Loading…
Regional Japanese drugstore chain based in Shizuoka, selling OTC drugs, cosmetics and daily goods.
Regional Japanese drugstore chain based in Shizuoka, selling OTC drugs, cosmetics and daily goods.
Moat: narrow (distribution). Regional drugstore network scale, smaller than national chains like Sundrug/Ain.
Headquarters: Shizuoka, Japan · Founded: 1985 · Employees: 5,478
Size Create SD (3148.T) is a Japan Consumer Staples company (Drugstore Chains) with a market value of $1.30B, the 627th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥3,230 on 6 Nov 2026.
Performance Over six months the shares fell 1.5%, against +2.9% for the median peer and +1.8% for the Japan market (cap-weighted) — 8th lowest of 18 in its peer set.
Growth Revenue grew 8.7% over the last twelve months (peer median +7.1%); the operating margin is 4.7% (peer median 4.8%).
Valuation It trades at 0.3× enterprise value to sales against a peer median of 0.8× (2nd cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -20 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.3 points above its cost of capital (5.0% WACC).
Next results Next results expected around 12 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥505B | ¥497B | ¥457B | ¥422B | ¥381B |
| Revenue growth | — | +9% | +8% | +11% | — |
| Gross profit | ¥122B | ¥121B | ¥114B | ¥105B | ¥98.8B |
| EBITDA | ¥30.4B | ¥30.5B | ¥28.3B | ¥25.2B | ¥23.3B |
| Net income | ¥16.8B | ¥17.0B | ¥15.7B | ¥13.7B | ¥12.9B |
| Free cash flow | n/a | ¥9.22B | ¥6.10B | ¥5.26B | ¥3.03B |
| Capital expenditure | n/a | ¥16.7B | ¥17.9B | ¥16.2B | ¥16.4B |
| Total debt | ¥1.05B | ¥1.41B | ¥0 | ¥1.00M | ¥6.00M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Create SD 3148.T | $1.30B | -2% | +9% | 5% | 0.3× | -11.5% |
| Sugi 7649.T | $3.27B | -23% | +9% | 5% | 0.5× | -9.7% |
| Sundrug 9989.T | $2.77B | -1% | +4% | 5% | 0.5× | -8.0% |
| Ain 9627.T | $1.23B | -2% | +42% | 4% | 0.4× | -6.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3148.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.5% | +2.1% | 8th highest of 18 |
| 6-month return | -1.5% | +2.9% | 8th lowest of 18 |
| Distance from 52-week high | -9.1% | -24.3% | 6th highest of 18 |
| Revenue growth (TTM) | +8.7% | +7.1% | 8th highest of 18 |
| Operating margin | 4.7% | 4.8% | 8th lowest of 18 |
| EV / Sales | 0.3× | 0.8× | 2nd cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -11.5% | -6.5% | 3rd least demanding of 16 |
| Growth delivered (Del g) | +8.0% | +12.4% | 6th lowest of 16 |
| Hurdle (Req g minus delivered) | -19.5 pp | -20.6 pp | 8th most demanding of 16 |
| ROIC minus cost of capital | +8.3 pp | +6.8 pp | 7th highest of 18 |
| EV / EBITDA | 5.7× | 7.3× | 3rd cheapest of 9 |
| Net debt / EBITDA | -1.0× | -0.2× | 3rd least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Create SD 3148.T | Japan | $1.30B | -2% | +9% | 5% | 0.3× | -11.5% | +8.0% |
| Ain 9627.T | Japan | $1.23B | -2% | +42% | 4% | 0.4× | -6.5% | +16.9% |
| Yixintang Pharmaceutical 002727.SZ | China | $1.18B | +6% | -2% | 3% | 0.5× | -15.9% | +6.5% |
| LBX Pharmacy Chain Joint Stock 603883.SS | China | $1.69B | +7% | +3% | 5% | 0.8× | -10.9% | +9.7% |
| Shu Yu Civilian Pharmacy 301017.SZ | China | $872M | +9% | +9% | 2% | 0.9× | 4.0% | +17.4% |
| Anhui Huaren Health Pharmaceutical 301408.SZ | China | $829M | -35% | +15% | 8% | 1.2× | -6.0% | +23.3% |
| MedPlus Health Services MEDPLUS.NS | India | $769M | -31% | +21% | 4% | 1.1× | 18.5% | +17.6% |
| Genky DrugStores 9267.T | Japan | $723M | +3% | +8% | 5% | 0.6× | n/a | n/a |
| Guardian Pharmacy Services GRDN | United States | $2.68B | +17% | +10% | 6% | 1.8× | 4.1% | +16.8% |
| Beijing Konruns Pharmaceutical 603590.SS | China | $617M | -28% | +4% | 20% | 4.2× | 11.6% | +2.7% |
| Sundrug 9989.T | Japan | $2.77B | -1% | +4% | 5% | 0.5× | -8.0% | +5.8% |
| Cawachi 2664.T | Japan | $577M | +37% | -1% | 2% | 0.2× | -5.8% | 0.0% |
| Qol 3034.T | Japan | $567M | +38% | +7% | 6% | 0.4× | -16.2% | +12.4% |
| Luyan Pharma 002788.SZ | China | $555M | -30% | +3% | 3% | 0.5× | 0.1% | +6.5% |
| Sugi 7649.T | Japan | $3.27B | -23% | +9% | 5% | 0.5× | -9.7% | +10.9% |
| DaShenLin Pharmaceutical 603233.SS | China | $3.80B | +15% | +7% | 8% | 1.1× | -9.0% | +13.6% |
| Landfar Bio-medicine 000504.SZ | China | $395M | -16% | +497% | -2% | 3.5× | n/a | n/a |
| Yifeng Pharmacy Chain 603939.SS | China | $4.91B | +17% | +5% | 10% | 1.3× | -9.2% | +13.2% |